A phase I study of PXD101 in combination with 5-azacitidine (5-Aza) for advanced hematologic malignancies.

Trial Profile

A phase I study of PXD101 in combination with 5-azacitidine (5-Aza) for advanced hematologic malignancies.

Completed
Phase of Trial: Phase I

Latest Information Update: 31 Dec 2014

At a glance

  • Drugs Azacitidine (Primary) ; Belinostat
  • Indications Acute lymphoblastic leukaemia; Acute myeloid leukaemia; Acute promyelocytic leukaemia; Chronic myeloid leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes; Myeloproliferative disorders
  • Focus Adverse reactions; Pharmacodynamics
  • Most Recent Events

    • 22 Dec 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 22 Dec 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 18 Mar 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top